pharmaphorum22d
Roche's Tecentriq gets three years to prove itself on Cancer Drugs Fund
Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
Zacks.com on MSN2mon
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the ...
FierceBiotech3d
In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
Seeking Alpha15d
Roche: Currency Headwinds Are Masking Strong Growth Trends
And similar to Ocrevus Zunovo in multiple sclerosis, Roche recently received FDA approval for Tecentriq Hybreza, the subcutaneous version of the PD-L1 antibody. The growth of Tecentriq has stalled ...
FiercePharma28d
Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq
Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...
GlobalData on MSN2mon
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
FiercePharma20d
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
Roche doesn’t think so ... versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 ...
Yahoo Finance1mon
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for ...
Pharmabiz5d
Roche to present more than 40 abstracts across nine blood disorders at the 66th ASH meeting
Roche announced that it will present more than 40 abstracts ... targeting both FcRH5 and CD3 and Tecentriq (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and ...
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
Yahoo Finance27d
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
Shares of Jazz Pharmaceuticals JAZZ rose nearly 6% on Tuesday after it reported positive top-line results from the phase III IMforte study, which evaluated Zepzelca (lurbinectedin), combined with ...
Business Insider1mon
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...